SecBot SecBot
8-K ·Filed May 6, 2026

VNDA

Vanda Pharmaceuticals Inc.
MIXED
Impact 6/10
Horizonweeks Processed6mo ago SEC0001628280-26-031241
8-K Item 2.02: Earnings release
Actionable Insight ◆ Mixed

The EPS miss may drive short-term selling pressure, but the raised guidance and new product approvals (BYSANTI, NEREUS) provide upside catalysts. Monitor NEREUS and BYSANTI revenue trajectories in Q2 2026 for sustainable growth. Cash burn remains a concern.

DirectionMixed
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$6.39
T+0 close · May 6, 2026 · via day close
Latest settled
−18.15%
T+60 · $5.23
Vs SPY
−21.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 7 $6.39entry
  2. T+1 · 6mo ago 0.00%α −0.83% · $6.39
  3. T+5 · 6mo ago +0.63%α −0.88% · $6.43
  4. T+20 · 6mo ago −4.69%α −7.83% · $6.09
  5. T+60 · 4mo ago −18.15%α −21.99% · $5.23
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vanda Pharmaceuticals reported Q1 2026 revenue of $51.7M (+3% YoY), in line with modest growth, but EPS of -$0.82 missed the Street consensus of -$0.53 by 55% as net loss widened to $48.6M. Positives include 26% Fanapt growth, FDA approval of BYSANTI, NEREUS launch, and raised FY2026 revenue guidance to $240-290M (from $230-260M). The mixed results balance a significant EPS miss against strong pipeline and commercial catalysts.

Key Financial Metrics

EPS
−$0.82
est −$0.53 · -54.7%
Revenue
$51.7M
+3.4% YoY
Rating
miss
Guidance
$240 million to $290 million
raised
Gross Margin
93.89%

Key Facts

  • Q1 2026 total revenue $51.7M, up 3% YoY from $50.0M
  • Fanapt net product sales $29.6M, up 26% YoY
  • GAAP diluted EPS -$0.82 vs consensus -$0.53 (miss of 54.7%)
  • Net loss $48.6M vs $29.5M in Q1 2025
  • Cash and equivalents $202.3M, down $61.5M including $10M milestone to Eli Lilly
  • FY2026 revenue guidance raised to $240-290M (from $230-260M), including $10-30M from NEREUS
  • BYSANTI (milsaperidone) received FDA approval on Feb 20, 2026
  • NEREUS (tradipitant) launched via direct-to-consumer platform

Financial Impact

EPS miss of 54.7% vs consensus; revenue slightly above prior year but below undisclosed estimate; cash burn $61.5M in quarter

epsnet losscashrevenue guidance

Risk Factors

  • Cash burn rate accelerated ($61.5M in Q1); runway limited despite $202.3M balance
  • HETLIOZ sales declining 24% YoY, eroding base revenue
  • Execution risk for NEREUS and BYSANTI commercial launches
  • Heavy reliance on Fanapt for growth; pipeline products still early stage

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
82% bullish (11 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001628280-26-031241
Document: vnda-20260506.htm0001628280-26-031241
Document: 0001628280-26-031241-index-headers.html0001628280-26-031241
Document: 0001628280-26-031241-index.html0001628280-26-031241
Document: 0001628280-26-031241.txt0001628280-26-031241
8-K Data (Synthetic)0001628280-26-031241

Track record

8 reports on VNDA

Performance horizon

The track record builds as more bullish or bearish reports settle.

Filters
  1. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $3.99 Now $3.81 −4.51% settles Nov 20
  2. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $4.08 Now $3.81 −6.62% settles Nov 17
  3. Oct 28, 202619d ago 8-K Bullish 6/10 Entry $4.05 to $3.59 Now $3.81 −5.93% ▼ −11.36% −6.63% vs SPY
  4. Oct 27, 202620d ago SC 13G Neutral 4/10 Entry $4.00 to $3.88 Now $3.81 −4.75% ▼ −3.00% −2.29% vs SPY
  5. Oct 21, 202626d ago Press Release Neutral 1/10 Entry $4.05 to $4.05 Now $3.81 −5.93% · 0.00% −0.71% vs SPY
  6. Oct 9, 20265w ago SC 13G/A Neutral 4/10 Entry $4.54 to $4.09 Now $3.81 −16.08% ▼ −9.91% −8.42% vs SPY
  7. Jul 29, 202615w ago Press Release Neutral 1/10 Entry $5.18 Now $3.81 −26.45% No price data
  8. May 6, 202627w ago 8-K Mixed 6/10 Viewing Entry $6.39 to $6.43 Now $3.81 −40.38% ▲ +0.63% −0.88% vs SPY
Showing 8 of 8

US Market Status

Market Closed · Opens in 6h 34m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 6, 2026